Fidaxomicin clinical trials
Also written Dificid, OPT-80 and PAR-101.
How each study uses Fidaxomicin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Fidaxomicin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 May 2011 · DIFICID · NDA 201699 (FDA, Drugs@FDA)
- European Union
- 5 Dec 2011 · Dificlir · EMEA/H/C/002087 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2012 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 11
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (5) · Astellas Pharma Europe Ltd. (3) · Astellas Pharma Europe B.V. (2) · Astellas Pharma Inc (1) · University of Michigan (1) · Duke University (1) · Hartford Hospital (1) · Astellas Pharma Global Development, Inc. (1)
Often tested with
Tested in the same studies.
Vancomycin (6) · Metronidazole (1) · Rosuvastatin (1) · Bean (1) · Fecal Microbiota Transplantation (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Fidaxomicin is the comparator. A study of two new drugs counts under both.
- 1Vancomycin · McGill University Health Centre/Research Institute of the McGill University Health Centre · next primary completion Jul 2031
Reaching primary completion within a year · 1
Studies that test Fidaxomicin.
- Mar 2027STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile InfectionNot applicable · Medical University of Warsaw
Studies
Open first, then newest update. How each study uses Fidaxomicin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel DiseaseNot yet recruitingPhase 4Brigham and Women's HospitalNCT06794944Written as FidaxomicinHow we know
- STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile InfectionNot yet recruitingNot applicableMedical University of WarsawNCT07120490Written as FidaxomicinHow we know
- Optimal Treatment for Recurrent Clostridium DifficileTerminatedPhase 4VA Office of Research and DevelopmentNCT02667418Written as FidaxomicinHow we know
- A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)CompletedPhase 3Astellas Pharma Europe B.V.NCT02218372Written as Fidaxomicin oral suspensionHow we know
- Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)CompletedPhase 4Astellas Pharma Europe Ltd.NCT02437591Written as fidaxomicinHow we know
- A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older PopulationCompletedPhase 4Astellas Pharma Europe Ltd.NCT02254967Written as FidaxomicinHow we know
- A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)CompletedPhase 3Astellas Pharma IncNCT02179658Written as OPT-80How we know
- Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile InfectionTerminatedPhase 3McMaster UniversityNCT02395848Written as FidaxomicinHow we know
- Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile InfectionTerminatedPhase 2University of AlbertaNCT03760484Written as Fidaxomicin 200 mgHow we know
- A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent InfectionsCompletedPhase 4University of MichiganNCT02692651Written as FidaxomicinHow we know
- A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune SystemTerminatedPhase 4Astellas Pharma Europe Ltd.NCT01775397Written as FidaxomicinHow we know
- Impact of Oral Antibiotic Treatment on C. DifficileCompletedPhase 4Duke UniversityNCT02057198Written as FidaxomicinHow we know
- Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)CompletedPhase 3Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01691248Written as fidaxomicinHow we know
- Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)CompletedPhase 2Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01591863Written as fidaxomicinHow we know
- Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile InfectionWithdrawnPhase 4University of Colorado, DenverNCT02464306Written as fidaxomicinHow we know
- Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus VancomycinCompletedPhase 4Hartford HospitalNCT01818141Written as FidaxomicinHow we know
- PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)CompletedPhase 3Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00468728Written as PAR-101/OPT-80How we know
- Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)CompletedPhase 3Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00314951Written as FidaxomicinHow we know
- OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)CompletedPhase 2Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00097422Written as OPT-80How we know
- Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord InjuryTerminatedPhase 4Baylor College of MedicineNCT02355938Written as Fidaxomicin 200 mgHow we know
See all 23 studies that test Fidaxomicin →
As the comparator · 4 — what is tested is compared with Fidaxomicin
- Vancomycin Taper to Prevent Recurrent Clostridioides DifficileRecruitingPhase 3McGill University Health Centre/Research Institute of the McGill University Health CentreNCT07328971Written as FidaxomicinHow we know
- Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs FidaxomicinCompletedPhase 3Mikrobiomik Healthcare Company S.L.NCT05201079Written as FidaxomicinHow we know
- Fecal Microbiota Transplantation for Relapsing Clostridium Difficile InfectionCompletedPhase 3University of AarhusNCT02743234Written as FidaxomicinHow we know
- A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)CompletedPhase 2Summit TherapeuticsNCT02784002Written as FidaxomicinHow we know
Codes
What other systems call Fidaxomicin · ClinicalTrials.gg INT006797
- MeSH (NLM) D000077732FidaxomicinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Z5N076G8YQFIDAXOMICINConfirmed FDA, NLM, Wikidata
- RxNorm 1111103One source FDA
- Wikidata Q111242331fidaxomicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66979FidaxomicinOne source FDA
- DrugBank DB08874One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077732 | Fidaxomicin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Z5N076G8YQ | FIDAXOMICIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1111103 | — | One source FDA |
| Wikidata | Q111242331 | fidaxomicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66979 | Fidaxomicin | One source FDA |
| DrugBank | DB08874 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.